Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Goodwill & Intangibles (2016 - 2026)

Ani Pharmaceuticals' Goodwill & Intangibles history spans 14 years, with the latest figure at $542.0 million for Q4 2025.

  • On a quarterly basis, Goodwill & Intangibles fell 9.94% to $542.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $542.0 million, a 9.94% decrease, with the full-year FY2025 number at $542.0 million, down 9.94% from a year prior.
  • Goodwill & Intangibles hit $542.0 million in Q4 2025 for Ani Pharmaceuticals, down from $562.3 million in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for ANIP hit a ceiling of $630.3 million in Q3 2024 and a floor of $32.5 million in Q2 2023.
  • Historically, Goodwill & Intangibles has averaged $325.9 million across 5 years, with a median of $273.4 million in 2022.
  • Biggest five-year swings in Goodwill & Intangibles: crashed 89.08% in 2023 and later surged 549.73% in 2024.
  • Tracing ANIP's Goodwill & Intangibles over 5 years: stood at $322.0 million in 2021, then decreased by 13.1% to $279.8 million in 2022, then decreased by 15.23% to $237.2 million in 2023, then soared by 153.69% to $601.8 million in 2024, then fell by 9.94% to $542.0 million in 2025.
  • Business Quant data shows Goodwill & Intangibles for ANIP at $542.0 million in Q4 2025, $562.3 million in Q3 2025, and $76.3 million in Q2 2025.